Edition:
United Kingdom

BiondVax Pharmaceuticals Ltd (BVXV.OQ)

BVXV.OQ on NASDAQ Stock Exchange Capital Market

5.30USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,859
52-wk High
$10.75
52-wk Low
$3.04

Select another date:

Tue, Nov 28 2017

BRIEF-Biondvax Pharmaceuticals Ltd Reports Qtrly Loss Per Share of NIS 0.01 ‍​

* BIONDVAX PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE NIS 0.01 ‍​ Source text for Eikon: Further company coverage:

BRIEF-BiondVax and NIH sign clinical trial agreement for phase 2 trial for universal flu vaccine

* BiondVax and NIH sign clinical trial agreement for a phase 2 trial in the U.S. with BiondVax's universal flu vaccine

BRIEF-Eastern Capital reports 7.3 pct passive stake in Biondvax Pharmaceuticals

* Eastern capital ltd reports 7.3 percent passive stake in Biondvax Pharmaceuticals Ltd as of September 18, 2017 - SEC Filing Source text: (http://bit.ly/2wSBhH6) Further company coverage:

BRIEF-Ibex Investors reports 5.5 pct passive stake in BiondVax Pharma

* Ibex Investors LLC reports 5.5 percent passive stake in BiondVax Pharmaceuticals Ltd as of Sept 14, 2017 - SEC filing Source text: (http://bit.ly/2fGw3nu) Further company coverage:

BRIEF-BiondVax announces pricing of public offering of American Depositary Shares

* BiondVax announces pricing of public offering of American Depositary Shares

BRIEF-BiondVax announces public offering of American Depositary Shares

* BiondVax announces public offering of American Depositary Shares

BRIEF-BiondVax Pharmaceuticals reports qtrly loss per share of NIS 0.07

* Qtrly loss per share NIS 0.07 Source text for Eikon: Further company coverage:

BRIEF-Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange

* Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange

BRIEF-BiondVax receives additional grant funding

* BiondVax Pharmaceuticals Ltd - ‍Israel innovation authority agreed to fund upto 40% of a nis 2.7 million budget towards ongoing development of M-001 Source text for Eikon: Further company coverage:

BRIEF-Biondvax Pharmaceuticals: trial meets both primary endpoints

* Biondvax reports positive Phase 2b clinical trial results for its universal flu vaccine

Select another date: